Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District

Abstract

Aim. A comparative analysis of the acquisition pattern of the renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in subjects of the Far Eastern Federal District.Material and methods. We used marketing data of pharmacy organizations (n=122) in 2019 in the Khabarovsk Krai (KK), Sakhalin Oblast (SO), and Primorsky Krai (PK). Intra-group analysis, price segmentation, and statistical analysis (Kruskal-Wallis test, Spearman’s correlation coefficient, factor analysis) were performed.Results. Angiotensin II receptor blockers (ARBs) are characterized by relatively low levels of sales in KK — 7,67%, in SO — 8,45%, and in PK — 9,75%. Angiotensin-converting enzyme (ACE) inhibitors remain one of the most used cardiovascular medications. In KK, their total share of sales is 28,9%, in SO — 31,12%, in PK — 26,93%. The leaders were losartan and enalapril. There were no significant differences in the distribution of sales between regions.Conclusion. Recently registered medicines (azilsartan, olmesar-tan, irbesartan, eprosartan), as well as substances with a narrow assortment/without generic drugs (zofenopril, quinapril, fozinopril), are more often characterized by low sales. The maximum sales of most popular ARBs (losartan, valsartan, candesartan) accrue to the price segment of 100-500 rubles. The most popular international nonproprietary names of the ACE inhibitors (captopril, lisino-pril, enalapril) are characterized by high sales in price segments <100 rubles.

Keywords

• кардиологические заболевания
• терапия
• приобретение препаратов
• ингибиторы ангиотензинпревращающего фермента
• блокаторы рецепторов ангиотензина